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Abstract
Background: Tissue engineering is an emerging field. Novel bioengineered skin substitutes and genetically derived growth
factors offer innovative approaches to reduce the burden of diabetic foot and venous leg ulcers for both patients and health care
systems. However, they frequently are very costly. Based on a systematic review of the literature, this study assesses the cost-
effectiveness of these growth factors and tissue-engineered artificial skin for treating chronic wounds.
Methods: On the basis of an extensive explorative search, an appropriate algorithm for a systematic database search was
developed. The following databases were searched: BIOSIS Previews, CRD databases, Cochrane Library, EconLit, Embase,
Medline, and Web of Science. Only completed and published trial- or model-based studies which contained a full economic
evaluation of growth factors and bioengineered skin substitutes for the treatment of chronic wounds were included. Two
reviewers independently undertook the assessment of study quality. The relevant studies were assessed by a modified version
of the Consensus on Health Economic Criteria (CHEC) list and a published checklist for evaluating model-based economic
evaluations.
Results: Eleven health economic evaluations were included. Three biotechnology products were identified for which topical
growth factors or bioengineered skin substitutes for the treatment of chronic leg ulceration were economically assessed: (1)
Apligraf®, a bilayered living human skin equivalent indicated for the treatment of diabetic foot and venous leg ulcers (five studies);
(2) Dermagraft®, a human fibroblast-derived dermal substitute, which is indicated only for use in the treatment of full-thickness
diabetic foot ulcers (one study); (3) REGRANEX® Gel, a human platelet-derived growth factor for the treatment of deep
neuropathic diabetic foot ulcers (five studies). The studies considered in this review were of varying and partly low
methodological quality. They calculated that due to shorter treatment periods, fewer complications and fewer inpatient episodes
the initial cost of the novel biotechnology products may be offset, making the treatment cost-effective or even cost-saving. The
results of most studies were sensitive to initial costs of the products and the evidence of effectiveness.
Conclusion:  The study results suggest that some growth factors and tissue-engineered artificial skin products feature
favourable cost-effectiveness ratios in selected patient groups with chronic wounds. Despite the limitations of the studies
considered, it is evident that health care providers and coverage decision makers should take not only the high cost of the
biotechnology product but the total cost of care into account when deciding about the appropriate allocation of their financial
resources. However, not only the cost-effectiveness but first of all the effectiveness of these novel biotechnology products
deserve further research.
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Background
The loss or failure of a tissue or organ due to congenital
abnormalities, disease, trauma, or aging is a frequent and
costly problem in health care. A new discipline, tissue
engineering, aims at developing biological substitutes to
repair, restore or improve tissue or organ function that has
been lost. It is an emerging interdisciplinary field that
applies the principles of physical sciences, engineering
and the life sciences. In this field, skin substitutes and
growth factors offer promise in the treatment of chronic
and acute wounds, burns, and various other skin disor-
ders.
Diabetic foot and venous leg ulcers are frequent and costly
complications of their underlying diseases and thus repre-
sent a critical issue for public health. The economic bur-
den of diabetic foot ulcers can be explained by several
factors [1]:
▪ Late management of patients with diabetes
▪ High recurrence and amputation rates
▪ Complexity of treatment modalities on patients with
osteomyelitis
▪ High morbidity and mortality rates after amputation
Novel biotechnology products may reduce this burden for
both the patient and the health care system in a cost-effec-
tive or even cost-saving way. To gain market access, man-
ufacturers increasingly have to establish not only the
efficacy of their products, but also whether these provide
a cure at an accepted cost per health gain.
The objective of this systematic review was to assess the
health economic evidence of bioengineered skin substi-
tutes and growth factors for the treatment of chronic leg
ulceration. The review forms part of a study on regenera-
tive medicine in Germany, funded by the German Minis-
try of Education and Research.
Methods
Only full health economic evaluations (cost-minimisa-
tion, cost-effectiveness, cost-utility or cost-benefit analy-
ses) of topical growth factors and bioengineered skin
products for the treatment of therapy-resistant chronic
wounds in English, French or German language were con-
sidered. Publications outside the above categories were
excluded from this review but used for reference tracking.
Also, the study did not include a systematic review of
effectiveness studies but only assessed those used within
the identified economic evaluations. Acellular artificial
skin and skin substitutes indicated only for use in burns
were excluded. Furthermore, economic evaluations
included in an earlier systematic review conducted by Ho
et al. [2] were excluded to avoid duplication of efforts in
reviewing and synthesizing evidence. On the basis of an
extensive explorative search, an appropriate algorithm for
a systematic database search was developed. The follow-
ing databases were searched to identify relevant literature:
BIOSIS Previews, Cochrane Library, Database of Abstracts
of Reviews of Effects (DARE), EconLit, Embase, HTA Data-
base, Medline, NHS Economic Evaluation Database (NHS
EED), and Web of Science. Additionally, the internet was
searched by Google and Google Scholar, and references of
recent economic evaluations and reviews were tracked.
The search was updated until and including July 2008. In
order to include studies published while this review was
being produced, the literature search was updated till the
end of November 2008. This update was restricted to the
PubMed database, which contains Medline. The explora-
tory search generated a set of eleven economic evaluations
of cell-derived wound care products as defined for this
review. The full Medline search strategy was developed as
follows: ("Biological Dressings" [Mesh] OR "Collagen"
[Mesh] OR "Skin, Artificial" [Mesh] OR "Bandages"
[Mesh] OR "Platelet-Derived Growth Factor" [Mesh])
AND ("Cost-Benefit Analysis" [Mesh] OR "economics"
[Subheading]). Six studies could be retrieved by using this
search algorithm. Table S1 provides further details on the
searches [see Additional file 1].
Two reviewers independently undertook the assessment
of study quality. Studies were assessed by an abbreviated
synthesis of two recent quality checklists for health eco-
nomic evaluations – the Consensus Health Economic Cri-
teria (CHEC) list [3] and a checklist for quality assessment
in decision-analytic models developed for health technol-
ogy assessment by Philips et al. [4]. The CHEC-list estab-
lished by Evers et al. is limited to systematic reviews that
include full health economic evaluations based on clinical
trials; that is, it is not suitable for economic evaluation
studies based on decision-analytic modelling or scenario-
analysis. Furthermore, the CHEC-list can be used only for
systematic reviews which are based on full health eco-
nomic evaluations and compare costs and outcomes of at
least two interventions, and in which the costs and out-
comes of those interventions are examined. Thus, key
modelling issues were evaluated using the quality assess-
ment tool for decision-analytic models established by
Philips et al. This checklist consists of three key dimen-
sions of quality: structure, data and consistency. The
abbreviated synthesis of the two quality checklists
described above consists of 23 items. Health economic
evidence was considered good, if the health economic
evaluations met the standard of transparency, if the
underlying results were stable in the sensitivity analysis
and if no unexplained inconsistencies between studies
were observed. Table S2 displays the results of the study
appraisal [see Additional file 2]. Characteristics of eco-
nomic evaluations are summarised in table S3 providingBMC Health Services Research 2009, 9:115 http://www.biomedcentral.com/1472-6963/9/115
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further details on study methodology [see Additional file
3]. Methodological issues of economic evaluations are
provided in table S4 [see Additional file 4].
Results
Eleven health economic evaluations were included. Three
biotechnology products were identified for which cell-
derived wound care products for the treatment of chronic
leg ulcers were economically assessed. All products are
already available on the market: (1) Apligraf, a bilayered
living human skin equivalent indicated for the treatment
of diabetic foot and venous leg ulcers (five studies); (2)
Dermagraft, a human fibroblast-derived dermal substi-
tute, which is indicated only for use in the treatment of
full-thickness diabetic foot ulcers of duration greater than
6 weeks that extend through the dermis, but without ten-
don, muscle, joint capsule, or bone exposure (one study);
(3) REGRANEX Gel (becaplermin), a human platelet-
derived growth factor for the treatment of deep neuro-
pathic diabetic foot ulcers (five studies). Table 1 provides
a brief overview of the products in the economic evalua-
tions.
Establishment of effectiveness
Many studies were based on randomised controlled clini-
cal trials. In three of the studies considered here [5-7],
becaplermin efficacy was derived from a meta-analysis
conducted by Smiell et al. [8] of four randomised studies
including 922 patients with diabetic foot ulcers. Kantor
and Margolis [9] took the becaplermin efficacy data from
a review by Wieman [10] of four multicentre, randomised,
placebo-controlled, parallel group studies. These four
studies included a total of 922 patients. Sibbald et al. [11]
used the multicentre double-blind placebo-controlled
phase III trial of 382 patients by Wieman et al. [12]. In the
Apligraf study by AÉTMIS [13], data were derived from the
pivotal clinical trial by Falanga et al. [14] including 293
venous ulcer patients to calculate the primary outcome
measure. Steinberg et al. [15] took effectiveness data from
the randomised prospective trial by Veves et al. [16] to
evaluate the cost-effectiveness of Apligraf in the treatment
of diabetic foot ulcers. Finally, in the Dermagraft study by
Segal and John [17], the US pivotal clinical trial by Naugh-
ton and colleagues [18] of 235 patients was used to assess
the mean cost per ulcer healed.
An overview of the sources for effectiveness data used in
the evaluations is given in table S5 [see Additional file 5].
Table 2 provides an overview of the studies and systematic
reviews used for the assessment of effectiveness.
Establishment of cost-effectiveness
As the identified health economic evaluations were too
heterogeneous and did not report adequate details for a
meta-analysis of results, we performed a narrative synthe-
sis of economic evidence including a description of all rel-
evant information regarding study methods and cost-
effectiveness results. In addition, in table 3, a summary
table is provided presenting key information relating to
type of ulcers, country, perspective, comparison of inter-
ventions, primary measure of health benefit and incre-
mental or average cost-effectiveness ratios.
Apligraf®
In our literature search, we identified 5 health economic
evaluations that assessed the cost-effectiveness of Apli-
graf® in the management of venous leg or diabetic foot
ulcers. All but one study were cost-effectiveness models
and most economic evaluations were funded by manufac-
tures/patentees of the products. Due to methodological
weaknesses (i.e. only average cost-effectiveness ratios,
small sample sizes, short time horizons, inadequate treat-
ment of uncertainty), the quality of the evidence was con-
sidered limited.
Table 1: Overview of human cell-derived wound care products for the management of chronic leg ulcers investigated by health 
economic evaluation
Product Description Indications Manufacturer
Apligraf® Bi-layered skin substitute: the 
epidermal layer is composed of 
human keratinocytes; the dermal 
layer is formed by human fibroblasts 
in a bovine type I collagen matrix
▪ Non-infected partial and full-
thickness venous leg ulcers
▪ Full-thickness neuropathic 
diabetic foot ulcers
Organogenesis, US
Becaplermin (REGRANEX® Gel) Clear colourless to straw-coloured 
gel, which contains 0.01% of the 
active substance becaplermin
▪ Deep neuropathic diabetic foot 
ulcers
Systagenix Wound Management, 
US
Dermagraft® Cryopreserved human fibroblast-
derived dermal substitute composed 
of fibroblasts, extracellular matrix, 
and a bioabsorbable scaffold
▪ Full-thickness diabetic foot ulcers Advanced BioHealing, USB
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Table 2: Characteristics of the randomised clinical trials for establishing effectiveness
Wound care 
product
Country Study period Number of patients/
study design
Initial ulcer size (cm2) Mean age Dressings Ulcers healed 
(%/duration)
Reference
Apligraf US 12 w + 3 m 
(follow-up)
112 (Apligraf), 96 
(saline-moistened 
gauze), RCT
2.97 intervention group 
(IG),
2.83 control group (CG)
58 IG,
56 CG
Weekly application
of Graftskin for a 
maximum of 4 weeks
56/12 w IG,
38/12 w CG
Veves et al. 
2001
Apligraf US 6 m + 6 m 
(follow-up)
146 (Apligraf plus 
compression), 129 
(compression alone), 
RCT
1.33 IG,
1.05 CG
60.2 IG,
60.4 CG
Maximum of 5 in weeks 
0–3, (IG), 1 in weeks 0–8 
(CG)
63/6 m IG,
48.8/6 m CG
Falanga et al. 
1998
Dermagraft US 32 w 109 (Dermagraft plus 
conventional therapy, 
126 (conventional 
therapy alone), RCT
≥ 1 Not stated Weekly application of 
Dermagraft in weeks 0–7
38.5/12 w IG,
31.7/12 w CG
Naughton et al. 
1997
Becaplermin US 20 w Study 1: 57 P, 61 B (30 
μg/g); Study 2: *; Study 
3: 68 GUC alone, 70 P, 
34 B (100 μg/g); Study 
4: 122 GUC, 128 B 
(100 μg/g); Total: 190 
GUC, 254 P, 193 B (30 
μg/g), 285 B (100 μg/g), 
478 B (all doses), 
review of 4 RCTs
Study 1: 7.2,
Study 2: 2.7,
Study 3: 2.2,
Study 4: 2.9
Study 1: 61,
Studies 2, 3: 58,
Study 4: 60
Becaplermin or placebo 
gel was applied topically 
once daily and covered 
with saline-moistened 
gauze.
Study 1: 48/20 w B (30 
μg/g), 25/20 w P; Study 2: 
*; Study 3: 44/20 w B 
(100 μg/g), 36/20 w P, 
22/20 w GUC; Study 4: 
36/20 w B (100 μg/g), 
32/20 w GUC
Wieman 1998
Becaplermin US 20 w *, meta analysis of 4 
RCTs
Study 1: 9.0 P, 5.5 (30 μg/
g); Study 2: *; Study 3: 2.5 
GUC, 2.2 P, 1.6 B (100 μg/
g); Study 4: 2.5 GUC, 3.2 B 
(100 μg/g)
Study 1: 58 P, 63 (30 
μg/g);
Study 2: *; Study 3: 60 
GUC, 57 P, 59 B (100 
μg/g); Study 4: 60 GUC, 
59 B (100 μg/g)
** * for efficacy results of 
individual studies;
combined analysis of 
treatment efficacy: 36/20 
w (GUC/P), 42/20 B (30 
μg/g), 50/20 B (100 μg/g)
Smiell et al. 
1999
Becaplermin US 20 w 127 P, 132 B (30 μg/g), 
123 B (100 μg/g), RCT
2.8 P, 2.6 B (30 μg/g), 2.6 B 
(100 μg/g)
58 P, 58 B (30 μg/g), 57 
B (100 μg/g)
** 50/20 w B (100 μg/g), 
36/20 w B (30 μg/g), 35/
20 w P
Wieman et al. 
1998
*: See Wieman et al. 1998; **: See Wieman 1998; B: becaplermin; CG: control group; GUC: good ulcer care; IG: intervention group; m: months; P: placebo; RCT: randomised controlled trial; w: 
weeks.B
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Table 3: Overview of health economic evaluations of cellular wound care products
Wound care 
product
Source: 
author, 
country, year
Type of 
ulcers
Interventions Perspective Type of econ. 
eval.
Primary 
outcome 
measures/source 
of effectiveness 
evidence
Cost-
effectiveness 
results 
(base case)
Sources of 
funding
Evidence
Skin Substitutes
Apligraf®a AÉTMIS, CA, 
2000
Venous leg (1) Compression 
alone
(2) Compression 
plus Apligraf® 
simultaneously
(3) Compression 
plus Apligraf® for 
hard-to-heal 
ulcers
Societal/health 
care system
CEAg Number of ulcer 
days averted/
Falanga et al. 1998
The incremental 
cost per ulcer day 
averted of 
compression and 
Apligraf® 
simultaneously used 
vs. compression 
alone was Can $26 
(US $22)d, and Can 
$22 (US $18)d when 
Apligraf® was 
restricted to hard-
to-heal ulcers. The 
price year was not 
reported.
Not stated Limitedh, i
Harding et al., 
UK, 2000
Venous leg (1) Saline gauze
(2) Granuflex®e
(3) Apligraf®
Health care 
payer
CEAg 12-week healing 
rate/literature 
review
The cost per wound 
healed was £541 
(US $828)d for saline 
gauze, £341 (US 
$522)d for 
Granuflex®, and 
£6,741 (US 
$10,323)d for 
Apligraf. The price 
year was 1999.
ConvaTec
Kerstein et al., 
US, 2001
Venous leg (1) Impregnated 
gauze
(2) DuoDERM®f
(3) Apligraf®
Health care 
payer
CEAg Number of 
persons healed/not 
healed after 12 
weeks/literature 
review
The cost per patient 
healed was US 
$2,939 for 
impregnated gauze, 
US $1,873 for 
DuoDERM®, and US 
$15,053 for 
Apligraf®. The price 
year was 2000.
ConvaTecB
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Meaume/
Gemmen, FR, 
2002
Venous leg (1) Saline gauze
(2) DuoDERM®f
(3) Apligraf®
Health care 
payer
CEAg Number of 
persons healed/not 
healed after 12 
weeks/literature 
review
The cost per patient 
healed was £1,722 
(US $1,832)d for 
saline gauze, £1,018 
(US $1,083)d for 
DuoDERM®, and £ 
15,920 (US 
$16,936)d for 
Apligraf®. The price 
year was 1999/2000.
ConvaTec
Steinberg et al. 
US, 2002
Diabetic foot (1) Saline-
moistened gauze 
alone
(2) Saline-
moistened gauze 
plus Apligraf®
Health care 
payer
CEA Number of ulcer-
free months 
gained, number of 
amputations or 
resections avoided/
Veves et al. 2001
The incremental 
cost of Apligraf® vs. 
control per ulcer-
free month gained 
was US $6,683, and 
US $86,226 when 
amputations or 
resections avoided 
were considered as 
benefit measures. 
The price year was 
2000.
Novartis
Dermagraft®b Segal/John, AU, 
2002
Diabetic foot (1) Convent. 
management 
alone
(2) Convent. 
management plus 
Dermagraft®
Health care 
payer
CEAg Number of healed 
weeks/Naughton 
et al. 1997
The incremental 
cost per additional 
healed week of 
Dermagraft® vs. 
control was A $383 
(US $292)d. The 
price year was 2000.
Smith + Nephew 
Pty. Ltd.
Limitedh, i, j
Growth Factors
Becaplermin 
(Regranex®c)
Ghatnekar et al., 
UK, 2000
Diabetic foot (1) Good wound 
care (GWC) 
alone
(2) GWC plus 
becaplermin
Health care 
system
CEAg Number of ulcer 
days averted/Smiell 
et al. 1999
Becaplermin plus 
GWC was found to 
be cost saving. The 
price year was not 
reported.
Not clearly stated Good
Table 3: Overview of health economic evaluations of cellular wound care products (Continued)B
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Ghatnekar et al., 
CH/FR/SE/UK, 
2001
Diabetic foot (1) GWC alone
(2) GWC plus 
becaplermin
Health care 
system
CEAg Number of ulcer-
free months 
gained/Smiell et al. 
1999
Becaplermin plus 
GWC was found to 
be cost saving in 
Sweden, Switzerland 
and the UK. The 
incremental cost 
per ulcer-free 
month gained of 
becaplermin over 
GWC alone was US 
$19 in France. The 
price year was 1999.
R.W. Johnson 
Pharmaceutical 
Research Institute
Kantor/
Margolis, US, 
2001
Diabetic foot (1) Standard care 
at a primary care 
setting (SC)
(2) Standard 
treatment at a 
specialised 
wound care 
centre (WCC)
(3) Treatment 
with platelet 
releasate at a 
wound care 
centre (PR)
(4) Becaplermin
Health care 
payer
CEAg Percentage of 
ulcers healed after 
20 weeks/Wieman 
1998
The incremental 
cost per additional 
1% of ulcers healed 
(most expensive vs. 
least expensive) was 
US $36.59 (SC vs. 
becaplermin), and 
US $70.86 
(becaplermin vs. 
WCC). Becaplermin 
dominated PR. The 
price year was 1999.
Curative Health 
Services, National 
Institutes of 
Health Geriatric 
Epidemiology
Persson et al. 
SE, 2000
Diabetic foot (1) GWC alone
(2) GWC plus 
becaplermin
Health care 
system
CEAg Number of ulcer-
months avoided/
Smiell et al. 1999
Becaplermin plus 
GWC was found to 
be cost saving. The 
price year was 1999.
R.W. Johnson 
Pharmaceutical 
Research Institute
Sibbald et al., 
CA, 2003
Diabetic foot (1) Best clinical 
care (BCC) alone
(2) BCC plus 
becaplermin
Societal CEAg Number of ulcer 
days averted/
Wieman et al. 1998
The ICER was Can 
$6 (US $5)d. The 
costs were 
estimated in 1998 
and updated to 
2002 costs using the 
Canadian Consumer 
Price Index for 
Personal and Health 
Care.
Janssen-Ortho 
Inc.
a Apligraf® is a registered trademark of Novartis. b Dermagraft® is a registered trademark of Advanced BioHealing, Inc. c Regranex® is a registered trademark of Systagenix Wound Management, 
Inc. d US $ converted by purchasing-power parity rates of the publication year. e Also known as DuoDERM® in France and in the US. f DuoDERM® is a registered trademark of Convatec. gCost-
effectiveness model. h Inappropriate treatment of uncertainty.i Small sample sizes.j Only average cost-effectiveness ratios. AÉTMIS: Agence d'évaluation des technologies et des modes 
d'intervention en santé; AU: Australia; BCC: best clinical care; CA: Canada; CEA: cost-effectiveness-analysis; CH: Switzerland; DE: Germany; FR: France; GWC: good wound care; ICER: 
incremental cost-effectiveness ratio; PR: platelet releasate; SE: Sweden; UK: United Kingdom; US: United States.
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An analytical prediction model was developed at AÉTMIS
(2001) [13] by assembling information for the following
treatment options of venous leg ulcer patients: compres-
sion alone, compression and Apligraf simultaneously,
compression and Apligraf for hard-to-heal ulcers which
are unresponsive to conventional therapy. To assess the
number of ulcer days averted, which was used as the ben-
efit measure in the economic analysis, data from the piv-
otal study by Falanga et al. (1998) [14] were obtained
(further information on clinical trial characteristics are
available in table 2). From both a health-care system per-
spective and a societal perspective the incremental cost for
each ulcer day averted was calculated to amount to Can
$26 when compression and Apligraf were used simultane-
ously, and Can $22 when compression and Apligraf were
used for hard-to-heal ulcers.
Harding et al. (2000) [19] combined a summary of pub-
lished studies and expert opinion to compare the cost-
effectiveness of saline gauze, the hydrocolloid dressing
Granuflex®  (UK trade name for DuoDERM®), and the
human skin equivalent Apligraf for venous leg ulcer
patients, over a 12-week treatment period. They identified
12 studies involving 843 ulcers, of which 205 were treated
with saline gauze, 509 with Granuflex, and 278 with Apli-
graf. Due to heterogeneity across studies, only the percent-
age of ulcers healed was reported and used for the
effectiveness estimate. The views of a European panel of
four wound-care specialists on the issue of resource utili-
sation and costs were used to design protocols of care
where data were not available from the literature. No sum-
mary measure of benefit was provided in the economic
analysis. Cost-effectiveness was calculated from a health-
care payer's perspective as the total medical cost of care of
the cohort divided by the number of healed wounds,
which yielded a cost per healed wound of £342 for Granu-
flex (nurse time £97, compression £121, dressing £124
and other £0), £541 for saline gauze (nurse time £327,
compression £166, dressing £48 and other £0), and
£6,741 for Apligraf (nurse time £70, compression £144,
dressing £6,526 and other £1). An incremental cost-effec-
tiveness ratio was not calculated.
Kerstein et al. (2001) [20] undertook a study in the United
States, similar to that by Harding et al. [19], with a
broader literature review to assess the cost-effectiveness of
gauze dressings impregnated with saline, paraffin or zinc
oxide, as compared with hydrocolloid dressings, and
human skin construct (Apligraf) in venous leg ulcer
patients. They included 18 studies and identified 223
patients on impregnated gauze dressings, 530 on hydro-
colloid dressings, and 130 on Apligraf. The data on effec-
tiveness were derived from a review of published studies.
The benefit measure used in the economic analysis was
the number of persons healed or not healed in a hypothet-
ical managed-care plan with 100,000 covered lives. The
average cost per patient healed was lowest with the hydro-
colloid dressing DuoDERM (US $1,873), followed by
impregnated gauze dressings at US $2,939, and then the
human skin equivalent Apligraf at US $15,053 over a
treatment period of 12 weeks.
Meaume and Gemmen (2002) [21] also used a similar
methodology to that adopted by Harding et al. [19] to
evaluate the cost-effectiveness of saline gauze, the hydro-
colloid dressing DuoDERM (German trade name Varihe-
sive®  and UK trade name Granuflex), and Apligraf in
venous leg ulcer patients from a European and French per-
spective, respectively. The French perspective in this study
was provided by a panel of five French wound-care
experts. The European expert panel comprised four spe-
cialists from the UK, France, Germany, and Sweden. The
evidence on effectiveness was derived from a literature
review. The benefit measure used in the economic analysis
was the number of patients healed at 6 and/or 12 weeks
in a hypothetical cohort of 100,000. Although the treat-
ment patterns are different between the United Kingdom
and France, the pattern of cost-effectiveness per patient
healed was consistent with the study conducted by Hard-
ing et al. [19] with the hydrocolloid dressing DuoDERM
being most cost-effective at £2,763/1,018, followed by
saline gauze at £1,436/1,722 and Apligraf at £11,396/
15,920 from a European and a French perspective, respec-
tively.
In the economic analysis by Steinberg et al. (2002) [15]
the living skin equivalent Apligraf was compared to
saline-moistened gauze to assess the cost-effectiveness of
these two dressings in diabetic foot ulcer patients, on the
basis of data from a six-month, multicentre, randomised
trial [16]. In this trial, there were 112 patients in the inter-
vention group and 96 controls. The benefit measures used
in the economic analysis were the number of ulcer-free
months gained and the number of amputations or resec-
tions avoided. In comparison to controls, patients in the
living skin equivalent group had a higher average number
of ulcer-free months (2.3 in the intervention group vs. 1.5
in the control group) and a lower average number of
amputations or resections (5.4% in the intervention
group vs. 12.5% in the control group). With a follow-up
of six months, the incremental cost-effectiveness ratio of
Apligraf over saline-moistened gauze was US $6,683
when the benefit measure was based on the number of
ulcer-free months gained, and US $86,226 when amputa-
tions or resections avoided were considered.
Dermagraft®
Segal and John (2002) [17] used observational case stud-
ies and a Markov model to evaluate the cost-effectiveness
of Dermagraft in addition to conventional managementBMC Health Services Research 2009, 9:115 http://www.biomedcentral.com/1472-6963/9/115
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in diabetic patients with neuropathic foot ulcers. The
Markov model was used to assess average cost per ulcer
healed, on the basis of effectiveness data from the pivotal
clinical trial [18]. The benefit measures used in the model
were the incremental healed weeks. On the basis of an
observational case study of 27 hard-to-heal ulcers an alter-
native cost-effectiveness estimate was established, using a
prospective analysis of resource use and cost for Derma-
graft. A survey in the specialist clinic setting was used to
assess the average cost of conventional management. On
the basis of the Markov model, the average cost per ulcer
healed was A $10,906 with conventional management
and A $12,128 with Dermagraft as an additional treat-
ment option. Using the results of the observational case
studies, the average cost to treat an ulcer was A $12,500
prior to Dermagraft treatment and A $4,682 after starting
Dermagraft treatment respectively.
Becaplermin (REGRANEX® Gel)
In our literature search, we found 5 economic evaluation
studies that assessed the cost-effectiveness of becaplermin
in the management of diabetic foot ulcers. All studies were
cost-effectiveness models. Most of these cost-effectiveness
analyses were funded by pharmaceutical companies or
coauthored by their employees, and reported results that
favoured the sponsor's product. The quality of the evi-
dence was considered high.
The following three studies [5-7] used the same source of
effectiveness evidence. However, country-specific patterns
of resource usage and prices have a high impact on cost-
effectiveness estimates. Therefore, to ensure that country-
specific differences in treatment patterns and cost esti-
mates are appropriately accounted for, the findings of
these studies are reported here separately.
Persson et al. (2000) [5] used a Markov model to evaluate
the cost-effectiveness of using becaplermin gel in combi-
nation with good wound care, as opposed to good wound
care alone, to treat diabetic patients in Sweden who pre-
sented neuropathic, lower extremity ulcers. As part of a
recent study on the cost of illness, a Markov model was
developed [22]. With that as a starting point, the authors
developed a more complete model of diabetic lower
extremity ulcers. Data on resource usage were derived
from a series of Swedish studies [23-26]. The becaplermin
efficacy was taken from a combined analysis of four ran-
domised studies [8]. The primary benefit measure used in
the model was the number of ulcer-days averted. In com-
parison to controls, patients in the intervention group had
a higher average number of ulcer-free months (4.22 in the
intervention group vs. 3.41 in the control group) and a
lower average number of amputations (5.91% in the
intervention group vs. 6.50% in the control group). The
average expected costs were US $12,078 for good wound
care alone and US $11,708 for becaplermin.
In the economic analysis by Ghatnekar et al. (2000) [6] a
similar Markov model to that developed by Persson et al.
[5] was used to evaluate the cost-effectiveness in the UK of
becaplermin gel as an adjunct therapy to good wound care
in diabetic foot ulcer patients. Data on resource usage
were taken primarily from a Swedish study [25]. To ensure
the generalisability of the study results to the UK setting,
they were reviewed by an expert panel of UK physicians.
Data on becaplermin efficacy were drawn from the analy-
sis by Persson et al [5]. The primary benefit measure used
in the model was the number of ulcer-days averted. As in
the analysis by Persson et al. [5] the average number of
months spent in the healed state rose by 24% from 3.41
to 4.22 and the average number of amputations fell from
6.50% to 5.91% – a decline of 9%. The average expected
costs over a 12-month time horizon were £10,880 for
good wound care alone and £10,403 for treatment with
becaplermin.
Ghatnekar et al. (2001) [7] used the same Markov model
as the one developed by Persson et al. [5] to assess cost-
effectiveness in four European countries (France, Sweden,
Switzerland, UK) of becaplermin as an adjunct treatment
option to good wound care alone in patients with diabetic
foot ulcers. Another objective was to address the issue of
generalisability by analysing the effect of different
resource use patterns on the economics of managing dia-
betic foot ulcers. Data on effectiveness evidence for beca-
plermin were drawn from a pooled analysis of four
randomised trials [8]. Resource data were primarily taken
from a series of Swedish studies [23-25]. The primary ben-
efit measure used in the model was the number of ulcer-
months avoided. The expected number of months in the
healed state was higher in the becaplermin group, 4.22
months vs. 3.41 months – an increase by 24%. Further-
more it was assumed that the average number of amputa-
tions would decline by 9%, from 6.50 to 5.91 per 100
patients. The average expected costs over a 12-month time
horizon in the becaplermin group and the control group
respectively were US $11,977/11,993 for France, US
$12,168/11,783 for Sweden, US $14,112/13,832 for Swit-
zerland, and US $17,601/17,133 for the UK.
Kantor and Margolis (2001) [9] used published literature
and a database to assess the cost-effectiveness of various
treatment options for diabetic neuropathic foot ulcers.
The following treatment strategies were considered: stand-
ard care, standard treatment in a wound care centre, beca-
plermin, or platelet releasate. The becaplermin data were
taken from a meta-analysis conducted by the authors on
published studies of becaplermin gel 0.01% [10]. The
measure of benefit used in the economic analysis was the
percentage of ulcers healed. At 20 weeks of care the per-
centages of ulcers healed were 30.9% for standard care,
43% for becaplermin, 36.8% for platelet releasate, and
35.6% for treatment in a wound care centre. The incre-BMC Health Services Research 2009, 9:115 http://www.biomedcentral.com/1472-6963/9/115
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mental cost per patient of increasing by 1% the chance of
healing at 20 weeks was US $36.6 for standard care vs.
becaplermin, and US $70.86 for becaplermin vs. treat-
ment in a specialised wound care centre. At this time,
becaplermin was superior to platelet releasate, as a more
effective and less costly treatment.
In the economic analysis by Sibbald et al. (2003) [11] a
decision tree was used to assess the cost-effectiveness of
becaplermin as an adjunct treatment option available to
best clinical care in patients with nonhealing neuropathic
diabetic foot ulcers. The effectiveness data were taken
from a randomised controlled clinical trial of 251 diabetic
patients [12]. The benefit measure used in the economic
analysis was the number of ulcer-days averted. The
number of ulcer-days per patient was 237 in the interven-
tion group and 211 in the control group over a one year
time horizon. Based on the model, the incremental cost-
effectiveness ratio was Can $6 per ulcer-day averted.
While the cost-effectiveness of tissue engineered skin was
considered poor in three studies [19-21], one study found
it to be more cost-effective than compression alone [13].
This difference could be explained by the assumptions
made in each analysis, most importantly the frequency of
tissue engineered skin application in each model. Table 3
provides an overview of the economic evaluations. As
described in the methods section, the last column is based
on an appraisal of studies by two independent reviewers
according to two published quality checklists.
Comparison of the results to other studies
Ho et al. [2] included in their review three cost-effective-
ness analyses of Apligraf [27-29], and one cost-effective-
ness study of Dermagraft [1]. Studies assessed by that
review were excluded from the present analysis to avoid
'double counting' of evidence, thus enhancing the effi-
cient use of resources. A summary can be found in Table 4.
In the four health economic evaluations, univariate and
multivariate sensitivity analyses respectively were con-
ducted on probabilities and costs. The results of the sensi-
tivity analyses showed that the models were generally
robust to almost all variations in model inputs. The study
results by Sibbald et al. [29] were sensitive to changes in
the time loss from usual daily activities, in which case
Apligraf plus four-layer bandage became the dominant
treatment modality. In the analysis by Schonfeld et al.
[28], when the cost of hospitalisation for patients in the
Apligraf group was doubled, Apligraf was no longer the
dominant strategy. In the economic evaluation by Rede-
kop et al. [27], the incremental cost-effectiveness ratio was
seen to be sensitive to the required number of applica-
tions of Apligraf, to amputation costs and differences in
infection rate. For all three parameters the results of the
incremental cost-effectiveness ratios ranged from cost-
effective to cost-saving.
Discussion
As no evaluation met all quality criteria, the evidence can
in general be considered limited.
Establishment of effectiveness
In none of the studies the clinical evidence was solely
based on the 'gold standard' of randomised, clinical trials.
Instead, cost-effectiveness was frequently modelled on the
basis of observational data and, in some cases, supple-
mented by the author's assumptions and/or expert opin-
ions.
All studies used condition-specific measures of benefit:
percentage of ulcers healed [9,19-21], ulcer-days averted
[6,11,13], additional healed weeks [17], ulcer-free
months gained [5,7,15] and amputations avoided [15].
While these may represent standard effectiveness meas-
ures of wound care, these cost-effectiveness ratios do not
allow for a meaningful comparison of cost-effectiveness
across disease areas or a comparison with societal willing-
ness to pay for a health gain. A more generic measure, for
example the quality-adjusted life-years, would be desira-
ble. Various studies considered health-related issues on
overall quality of life in patients with venous leg and dia-
betic foot ulcers respectively [30-33], but our literature
research identified no cost-utility analyses in this field.
This may be due to a lack of studies that take into account
quality of life in the health care interventions considered
here. Only one study could be identified, in which quality
of life with relation to the use of Apligraf was taken into
account [34].
An important limitation of the publications considered in
this review was the short time horizon. In three studies
[19-21], the time horizon was twelve weeks, which gives
rise to the following problem [20]: as a result of the short
time horizon, the average healing cost is comparatively
high, because dressings are applied in the first weeks of
treatment. Thus, over a longer time horizon, the average
treatment cost may be expected to become lower. In some
studies, the time horizon was limited to that used in the
primary studies. Two studies considered longer time peri-
ods in one-way sensitivity analyses [5,6]. The authors of
these studies suggest that the cost-effectiveness may be
more favourable over a longer time horizon.
In some studies, the results were reported as cost per
wound healed. This does not consider additional factors,
such as the length of time needed for the wound to heal,
pain, or other complications which may arise during the
healing process. It may be that a particular treatment has
a higher cost per wound healed compared to other treat-
ments, but helps heal a larger number of wounds.B
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Table 4: Overview of economic evaluations included in Ho et al. 2005
Wound care 
product
Source: author, 
country, year
Type of ulcers Interventions Perspective Type of 
economic 
evaluation
Primary outcome 
measures/source of 
effectiveness evidence
Cost-effectiveness results 
(base case)
Sources of 
funding
Evidence
Skin Substitutes
Apligraf® Redekop et al., 
NL, 2003
Diabetic foot (1) GWC alone
(2) GWC plus 
Apligraf®
Societal CEA Number of ulcer-free 
months gained and 
amputations avoided/
Veves et al. 2001
Treatment with Apligraf 
(more effective and less 
costly) dominated over 
GWC alone.
Novartis Limited
Schonfeld et al., 
US, 2000
Venous leg (1) Unna's boot
(2) Apligraf®
Health care 
payer
CEA Number of healed 
months and total % 
healed at 12 months/
Falanga et al. 1998
Apligraf was the dominant 
strategy (more effective 
and less costly).
Novartis
Sibbald et al., 
CA, 2001
Venous leg (1) 4-layer 
bandage system 
alone
(2) 4-layer 
bandage system 
plus Apligraf®
Societal/Health 
care payer
CEA Number of ulcer days 
averted/Falanga et al. 
1998
Over a 3-month time 
horizon, the incremental 
cost per ulcer day averted 
with Apligraf plus 4-layer 
bandage system over 4-
layer bandage system 
alone was Can $14 (US 
$12)* from both 
perspectives.
Novartis
Dermagraft® Allenet et al., 
FR, 2000
Diabetic foot (1) Standard 
treatment
(2) Dermagraft®
Societal CEA Number of additional 
ulcers healed/
Naughton et al. 1997
The incremental cost per 
additional ulcer healed of 
Dermagraft® over 
standard treatment was 
FF38,784 (US $41,260)*.
French Ministry 
of Health
Limited
*: US $ converted by purchasing-power parity rates of the publication year; CA: Canada, CEA: cost-effectiveness-analysis; FR: France, GWC: good wound care; NL: Netherlands; US: United 
States.BMC Health Services Research 2009, 9:115 http://www.biomedcentral.com/1472-6963/9/115
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Establishment of cost-effectiveness
None of the identified products fully met all quality crite-
ria and frequently deviated from current standards of
health economic evaluation. For example, Harding et al.
[19], Kerstein et al. [20], and Meaume and Gemmen [21]
did not calculate incremental cost-effectiveness ratios but
only reported average cost-effectiveness. In many cases,
the perspective was not stated clearly or substantiated.
Also, quantities of consumed resources or details on dis-
counting were often not given. Probabilistic sensitivity
analysis was conducted in none of the eleven health eco-
nomic evaluations. Most of the economic evaluations
relied on one-way sensitivity analyses.
The categories of costs included in the evaluations differed
substantially between studies. Most studies considered
only direct costs (e.g. outpatient clinic visits, hospital
days, physician office visits, homecare, laboratory and
diagnostic tests, debridement, dressing materials, ortho-
paedic appliances, costs of amputations). Indirect costs
were included in two evaluations only [11,13]. Intangible
costs were not evaluated. In many studies, a detailed
breakdown of the costs was not provided, the price year
was not reported, and the unit costs were not presented
separately from the quantities of resources used. Health
resource use was often estimated on the basis of expert
opinions.
The transferability of clinical and economic evidence is an
important issue in health economic evaluation [35].
Some authors noted that a limitation of their studies was
the lack of available data. In most evaluations, effective-
ness data came from clinical trials conducted in the USA,
but the application of US data to European countries
could be controversial. Furthermore, the number of appli-
cations of skin substitutes may vary substantially between
settings. The issue of generalisability of study results to
other settings was extensively addressed only by one study
[7], in which four different European countries were con-
sidered. The study by Ghatnekar et al. (2001) revealed
substantial differences in treatment patterns and in the
nature of cost-savings across countries, owing to the dif-
ferences in the health care systems. In this context, reim-
bursement systems, relative prices, and treatment
practices are important issues that vary from country to
country [5]. In general, decision-makers in other health
care systems should investigate the cost-effectiveness of
tissue-engineered products in their own setting.
Discounting was of low importance since all costs were
incurred within a period of less than a year. However,
while many guidelines recommend equal discounting for
costs and effects, discounting of costs only was performed
in two studies [5,6].
Limitations of the present review
First of all, it must be stated that the choice of dressings
studied was dictated by the available fully published
health economic evaluations. Currently, only few chronic
leg ulcer treatment modalities provide sufficient details
from which to draw conclusions concerning cost-effec-
tiveness. Furthermore, only studies in English, French or
German could be included. The economic analyses were
appraised by a checklist on methodological quality and
the studies considered were rated only on the basis of
widely applicable criteria known to the authors. However,
good health economic evaluations are more than the sum
of their parts [36]. Even though the study appraisal was
based on the consensus of two independent reviewers, it
is nonetheless restricted by those reviewers' subjectivity.
Conclusion
Cell-derived wound care products in addition to standard
care generate very high costs. This is a consequence of the
attempt to increase the number of ulcers healed or ulcer-
free time. The economic evidence suggests that despite
their high initial costs, tissue-engineered wound care
products may be cost-effective or even cost-saving if their
use is restricted to such ulcers that are unresponsive to
healing. This is because the initial costs of novel biotech-
nology products may be offset by shorter treatment peri-
ods (i.e., higher healing rates and faster healing), fewer
complications (i.e. infection and gangrene that carry a
higher risk of amputation) and fewer inpatient episodes.
Due to the limitations of the studies included in this
review, future work should focus on well-designed stud-
ies, using appropriate methods for randomisation. Fur-
thermore, prospective studies should be conducted to
corroborate current study results. As the cost-effectiveness
of these treatment modalities may improve over time
[29], future health economic analyses should explore a
longer time horizon. Further research should also be car-
ried out to obtain better estimates of the clinical benefits,
since the findings of most studies were shown to be sensi-
tive to these parameters, and further investigations into
the effectiveness of the various treatments in routine clin-
ical practice and patient-related outcomes (such as health-
related quality of life) are needed to complement the
existing data on cost-effectiveness and help reimburse-
ment agencies make informed coverage decisions.
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